1WHO. OIE Echinococcosis in humans: clinical aspects, diagnosis and treatment//Eckert J, Gemmel MA, Meslin FX, et al. Who/Oie manual on echinococcosis in humans and animals: a public health problem of global concern. Paris: World Organisation for Animal Health, 2001: 47.
2WHO Informal Working Group Echinococcosis. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull World Health Organ, 1996, 74: 231-242.
3Wen H, New RR, Muhmut M, et al. Pharmacology and efficacy of liposome-entrapped alhendazole in experimental secondary alveolar echinococcosis and effect of co- administration with cimetidine. Parasitology, 1996, 113: 111 -121.
4Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar eehinococcosisin humans. ActaTrop, 2010, 114: 1-16.
5Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology, 2000, 121 Suppl: Sl13- 132.
6Mirfazaelian A, Rouini MR, Dadashzadeh S. Dose dependent pharmacokinetics of albendazole in human. Biopharm Drug Dispos, 2002, 23: 379-383.
7Miki D, Jevti M, ArsidKomljenovi G, et al. Impossibility of the treatment of inoperable liver multicystie echinococcosis due to adverse reactions to antihelminitics. Vojnosanit Pregl, 2009, 66: 833-839.
8Nuray A , Orenay S, Reyhan E, et al. Genotoxic effects of albendazole in patients medicated for cystic echinococcosis. Helminthologia, 2007, 44:57- 61.
9Tas A, KOklti S, Celik H. Loss of body hair as a side effect of albendazole. Wien Kiln Wochenschr, 2012, 124: 220.
10Capan M, Keltner S, Thalhammer F, et al. Intra-cystic drug concentration of albendazole sulphoxide in patients with Eehinococcus granulosus cysts. Am J Trop Med Hyg, 2009, 81: 712-713.
